ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Sirona Biochem Corp

Sirona Biochem Corp (SBM)

0.06
-0.005
(-7.69%)
Cerrado 13 Enero 3:00PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.06
Postura de Compra
0.06
Postura de Venta
0.065
Volume Operado de la Acción
66,000
0.06 Rango del Día 0.065
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
0.065
Precio de Apertura
0.065
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
253,604,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.00
Beneficio por acción (BPA)
-0.01
turnover
35k
Beneficio neto
-2.54M

Acerca de Sirona Biochem Corp

Sector
Unit Inv Tr, Closed-end Mgmt
Industria
Pharmaceutical Preparations
Sede
Vancouver, British Columbia, Can
Fundado
2006
Sirona Biochem Corp is listed in the Unit Inv Tr, Closed-end Mgmt sector of the TSX Venture Exchange with ticker SBM. The last closing price for Sirona Biochem was $0.07. Over the last year, Sirona Biochem shares have traded in a share price range of $ 0.00 to $ 0.00.

Sirona Biochem currently has 253,604,000 shares in issue. The market capitalisation of Sirona Biochem is $16.48 million. Sirona Biochem has a price to earnings ratio (PE ratio) of -6.00.

SBM Últimas noticias

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology

VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious...

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout

VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear...

GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient...

Sirona Biochem Engages Stonegate Healthcare Partners

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate...

SIRONA BIOCHEM Corporate Update April 2024

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear...

Sirona Biochem Announces Close of Private Placement

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private...

Sirona Biochem Announces 2023 Annual Meeting Results

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting...

Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its...

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its...

Sirona Biochem Provides Update on Loan

VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announce that, further to its news release on...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

SBM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Sirona Biochem?
El precio actual de las acciones de Sirona Biochem es $ 0.06
¿Cuántas acciones de Sirona Biochem están en circulación?
Sirona Biochem tiene 253,604,000 acciones en circulación
¿Cuál es la capitalización de mercado de Sirona Biochem?
La capitalización de mercado de Sirona Biochem es CAD 16.48M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Sirona Biochem?
Sirona Biochem ha negociado en un rango de $ 0.00 a $ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Sirona Biochem?
El ratio precio/beneficio de Sirona Biochem es -6
¿Cuál es el ratio de efectivo a ventas de Sirona Biochem?
El ratio de efectivo a ventas de Sirona Biochem es 600
¿Cuál es la moneda de reporte de Sirona Biochem?
Sirona Biochem presenta sus resultados financieros en CAD
¿Cuál es el último ingresos anual de Sirona Biochem?
El último ingresos anual de Sirona Biochem es CAD 35k
¿Cuál es el último beneficio anual de Sirona Biochem?
El último beneficio anual de Sirona Biochem es CAD -2.54M
¿Cuál es la dirección registrada de Sirona Biochem?
La dirección registrada de Sirona Biochem es WEWORK - 595 BURRARD STREET, VANCOUVER, BRITISH COLUMBIA, V7X 1L4
¿Cuál es la dirección del sitio web de Sirona Biochem?
La dirección del sitio web de Sirona Biochem es www.sironabiochem.com
¿En qué sector industrial opera Sirona Biochem?
Sirona Biochem opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SQGSpackman Equities Group Inc
$ 3.50
(354.55%)
59.45k
KLMKermode Resources Ltd
$ 0.01
(100.00%)
1.42M
GNFIGenifi Inc
$ 0.01
(100.00%)
2k
XBOTRealbotix Corp
$ 0.61
(84.85%)
6.9M
JADEJade Leader Corp
$ 0.04
(60.00%)
177k
AJAAJA Health and Wellness Inc
$ 0.035
(-53.33%)
2k
BYM.HBaymount Incorporated
$ 0.005
(-50.00%)
1,000
ETUE2gold Inc
$ 0.005
(-50.00%)
12.29k
ENTGEntourage Health Corp
$ 0.005
(-50.00%)
16.04k
WWA.PWhitewater Acquisition Corp
$ 0.14
(-48.15%)
5k
XBOTRealbotix Corp
$ 0.61
(84.85%)
6.9M
QNCQuantum Emotion Corp
$ 0.90
(-19.64%)
4.37M
GPUSAlset AI Ventures Inc
$ 0.185
(-11.90%)
4.1M
RHCRoyal Helium Ltd
$ 0.02
(0.00%)
3.47M
THRMTherma Bright Inc
$ 0.04
(-20.00%)
2.71M
sunspotter sunspotter 14 minutos hace
Glenn Miller’s still missing, and Emil Malak and Rich Inza are still crooks.
VPLM
Flobewan Flobewan 25 minutos hace
Marc loved your ides
tinojax tinojax 26 minutos hace
I usually enjoy a beer with my pizza...........I would like to know what's in the Kool Aid........
PLUG
mrfence mrfence 29 minutos hace
Here we are on the cusp of the Monsta $FMCC~ $FNMA~ Gains we've all been waiting for doin da Heebie Jeebie Dance, 😃😄😁😆😅😂!
[yt]MUB3ZR4F8vw?si=Z3oB5zc_RHMtCGEY[/yt]
FMCC FNMA
IVRT IVRT 45 minutos hace
In my opinion, there will likely be significant pressure on the share price leading up to the conference call. A sell-off could occur the day before, with the stock potentially bottoming out by the end of the investor call. I could be wrong, but I've seen similar patterns many times over the past 25
BMXI
DewDiligence DewDiligence 45 minutos hace
GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

ENTA
DewDiligence DewDiligence 46 minutos hace
GSK acquires—(private)—IDRx for $1B up-front + $150M contingency:

https://www.businesswire.com/news/home/20250112698434/en • Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

Guido2 Guido2 47 minutos hace
This is DUE DILIGENCE! Thank you Free Fannie.

https://x.com/freefannie/status/1878655047715991552?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ
FNMA
StockItOut StockItOut 53 minutos hace
That Xeriant PR excellently written with bullshit:

""After successfully completing 75% of the demanding NFPA 286 test," meaning = "after failing the NFPA 286 test by missing 25% of the approval target testing requirement,"

"the Company used the data to make several key
XERI
gitreal gitreal 56 minutos hace
You were actually partially right....BMXI has filed some SEC documents, some necessary (Form 1-A), some unnecessary (Form 4). And they do summarize a lot of the stuff that I think are fabrications....their production, mining operations, etc. Time will tell, but I think a lot of it (and probably
BMXI
RichieBoy RichieBoy 1 hora hace
Jim wrote a blurb about seeking more US business.

Help you out any? 🤨
AFFU
DesktopDR DesktopDR 1 hora hace
Any news or updates?
VPLM
Tahoe2468 Tahoe2468 1 hora hace
.0915 by Thursday....... 
KRTL
skitahoe skitahoe 1 hora hace
Remember GBM was redefined during the trial, thus some who were treated then had other forms of brain cancer. I believe the least we'll see in our label is brain cancer. Certainly GBM may be the deadliest of them, but treatment should work in all of them.

According to Google, GBM ha
NWBO
fuagf fuagf 1 hora hace
You are right about the crafty, evil, smart. Authoritarian methods have been in full view
in capturing America. While we work to do the right things they plot to capture the lot.
facts_matter14 facts_matter14 1 hora hace
If there weren’t suckers born every minute, there wouldn’t be POSRMX bag holders down as much as 99%, and there sure as hell wouldn’t be anybody believing there is a pipeline of products.






.
SRMX
StockItOut StockItOut 1 hora hace
Your "closer" keeps getting extended. Then again extended. Then again extended. -- Consider that end. Now expired, horizon end now reached, and the view clarifies and we see it to be your desperation from years ago ongoing still, to pump this at any expense, where you attempt to instill FOMO to hold
XERI
fuagf fuagf 1 hora hace
He would smother any question with words.
Shawonsarker84 Shawonsarker84 1 hora hace
$HMBL Sorry HMBL investors. XTIA now broke the record 2.7B share volume traded before the reverse split.



https://x.com/shawonsarker84/status/1878696680088019193?t=rZlhkn2Jos4vWKxxQgXGfA&s=19
HMBL XTIA
chen1992 chen1992 1 hora hace
https://www.energy.senate.gov/hearings/2025/1/hearing-to-consider-the-nomination-of-mr-chris-wright-to-be-secretary-of-energy

https://www.commerce.senate.gov/2025/1/full-committee-nomination-hearing_2#:~:text=U.S.%20Senator%20Ted%20Cruz%20(R,Wednesday%2C%20January%2015%2C%20
TGLO
FNM500K FNM500K 1 hora hace
Oh noooooo.....
FNMA
StockItOut StockItOut 1 hora hace
OTC filings and attorney statements. my error.

Point that it is on you to prove your claim, that:
"There's no contract employees. There's no production shafts."

Likewise for the company to do so, as we wait for an audit, apparently indefinitely.

I
BMXI
Money4Nothing-M4N Money4Nothing-M4N 2 horas hace
Definitely excited to hear about batch 5. I believe we should hear news very soon. if they began batch 5 immediately after batch 4 then 5 is overdue.

And in light of last week's PR about Darwin's Bark Dragline silk, I'm expecting KBLB to have the attention of the DOD once again.
KBLB
rx7171 rx7171 2 horas hace
Too bad no mention of the degree of brain atrophy of the Blar treated patients reverting to close to normal aging compared to the MAB treated patients having accelerated rate of atrophy.

To me this is a bio marker that sets the two therapies at extreme ends of the plus minus continuum
AVXL